19 results about "Fatty acid biosynthesis" patented technology

This invention belongs to the field of biomedical technology, specifically relating to a compound extracted from *Acer buergerianum* (a type of shrub), its extraction method, and its application in the preparation of drugs for the prevention or treatment of non-alcoholic fatty liver disease. This invention is the first to obtain a natural compound with a novel structure from *Acer buergerianum*, and provides a method for its preparation. Activity studies were conducted, and experimental data show that the compound exhibits low cytotoxicity and no significant cytotoxicity to normal cells. It can inhibit the expression of fatty acid synthases ACC, ACLY, and FAS, thereby inhibiting de novo fatty acid synthesis in cells, suppressing lipid droplet accumulation, and reducing cellular lipid levels. This compound has broad application prospects in the preparation of drugs for the prevention or treatment of non-alcoholic fatty liver disease.

The invention discloses a difunctional alcohol dehydrogenase derived from Geobacillus thermodenitrifis, the difunctional alcohol dehydrogenase takes NAD < + > as a cofactor, can specifically catalyze a continuous oxidation reaction of omega-hydroxy fatty acid, and catalyzes the omega-hydroxy fatty acid to synthesize alpha, omega-binary fatty acid through single enzyme catalysis without an aldehyde intermediate. The alcohol dehydrogenase has dual catalytic functions of alcohol oxidation and aldehyde oxidation, the oxidation process from hydroxymethylene to carboxyl can be completed in one step, the reaction steps are simplified, accumulation and separation of intermediate aldehyde are avoided, the conversion efficiency is improved, and the alcohol dehydrogenase is alpha, omega-dibasic fatty acid and is a novel alcohol dehydrogenase. The invention provides a simple and efficient biocatalysis way for biosynthesis of dodecanedioic acid, especially dodecanedioic acid, and has important industrial application value.

The invention provides a composition, cell culture and application of the composition in differentiation of human pluripotent stem cells to myocardial cells and / or construction of human-derived heart organoid, and belongs to the technical field of cell engineering. The invention provides a composition. The composition comprises a fatty acid receptor antagonist, a fatty acid synthetase inhibitor and a fatty acid oxidation activator. The composition provided by the invention can regulate cell metabolism, breaks through the contradiction that the proliferation capacity and the cell maturity cannot be obtained at the same time in the traditional technology, can maintain the myocardial cells in a proliferation stage, and obtains the myocardial cells with relatively mature structures and functions, and the contractility of 3D heart organs constructed by the myocardial cells is greatly improved. The invention provides a high-quality cell source for myocardial regeneration treatment, high-throughput drug cardiotoxicity screening and heart disease mechanism research, and has remarkable clinical application value and industrialization prospect.

The invention relates to Escherichia coli ML001, a specific bacteriophage thereof and an application of the Escherichia coli ML001 in preventing alcoholic liver diseases. The Escherichia coli strain ML001 and the specific bacteriophage thereof are preserved in China General Microbiological Culture Collection Center (CGMCC). Animal experiments prove that the bacteriophage can effectively reduce the level of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase in the plasma of an alcoholic liver disease model mouse, which indicates that the bacteriophage has a definite liver protection function. The histopathologic examination further shows that after the phage is administered, the number of lipid droplets in the liver of the mouse is obviously reduced, and the liver lipid accumulation is effectively relieved. On the molecular mechanism level, the bacteriophage can down-regulate expression of fatty acid synthesis genes Srebf1 and Acly at the same time and inhibit a lipid synthesis pathway; meanwhile, the expression of a chemotactic factor Ccl6 is reduced, and the inflammatory response of the liver is relieved.

The present disclosure relates to an antiviral pharmaceutical composition including an estrogen-related receptor γ (ERRγ) inhibitor as an active ingredient. According to embodiments of the present disclosure, an antiviral pharmaceutical composition containing an ERRγ inhibitor as an active ingredient has antiviral effects. In particular, the antiviral pharmaceutical composition is effective in preventing or treating RNA virus infections. Specifically, the ERRγ inhibitor, especially an ERRγ inverse agonist, may exhibit broad-spectrum antiviral effects by inhibiting ERRγ activity in RNA virus-infected cells, thereby blocking fatty acid biosynthesis mediated by sterol regulatory element-binding protein 1c (SREBP1c).

The application provides application of a LuPDH-E1beta1 gene in regulating plant fatty acid synthesis, and after overexpression of the LuPDH-E1beta1 gene in plants, the amount of plant fatty acid synthesis can be increased. The application also provides application of the LuPDH-E1beta1 gene in regulating plant salt tolerance and drought resistance, and after overexpression of the LuPDH-E1beta1 gene in plants, the salt tolerance and drought resistance of a PDH-E1beta1 gene deletion plant can be increased. Through exploration of the function of the LuPDH-E1beta1 gene in plant seed oil metabolism and response to abiotic stress, the application of the LuPDH-E1beta1 gene in regulating plant fatty acid synthesis and salt tolerance and drought resistance is given, and a blank in the application of the LuPDH-E1beta1 gene in genetic engineering is filled.

This invention discloses a GhLACS4 gene that regulates the oil content of plant seeds and its applications, belonging to the field of molecular biology. The nucleotide sequence of the GhLACS4 gene is shown in SEQ ID NO.1, and the amino acid sequence of its encoded protein is shown in SEQ ID NO.2. This gene mainly participates in fatty acid synthesis and affects the accumulation of oil in seeds by converting free fatty acids 18:2 into 18:2-CoA, thus providing gene resources for breeding high-oil cotton.

The invention discloses application of EIF3H in treatment of liver cancer. Research finds that MASH and hepatic fibrosis can be relieved by down-regulating fatty acid de novo synthesis of EIF3H, and tumorigenesis in an HCC mouse model induced by DEN + HFHC and HDTI + HFHC is inhibited. In mechanism, EIF3H is combined with FASN, and KEAP1 mediated FASN ubiquitination is antagonized, so that the FASN protein is stabilized. Therefore, EIF3H is a FASN deubiquitinase which is not illuminated previously, and drives the MASLD-HCC process by promoting fatty acid metabolism reprogramming. The EIF3H-FASN axis can be used as a therapeutic target of liver cancer.

The invention discloses a fatty acid metabolism regulation gene mining method based on transcriptome data driving, a FindGene platform developed by the invention can efficiently integrate and standardize large-scale RNA-Seq data, systematic mining function related genes are analyzed through a weighted gene co-expression network, and the gene mining efficiency is improved. The limitation of dependence on small-scale experiments and manual screening in the past is broken through, and the efficiency and accuracy of key regulation gene screening are greatly improved. According to the schizosaccharomyces cerevisiae engineering strain QH-7 constructed by carrying out site-directed mutagenesis, overexpression and combined transformation on a key gene obtained by screening, the yield of fatty acid reaches 2.12 g / L and is increased by about 118.6% compared with that of a wild strain, and the biosynthesis efficiency of the fatty acid is greatly improved. According to the modified strain, the total fatty acid content is increased, meanwhile, the proportion of unsaturated fatty acids (C16: 1, C18: 1 and C18: 2) is remarkably increased, and the requirements for high-quality lipid raw materials in the fields of downstream biofuels, nutritional supplements and the like are met.

To provide use of isorhamnetin or pharmaceutically acceptable salts thereof in preparation of drugs for treating esophageal cancer in the technical field of biological medicines.SOLUTION: It has been found that isorhamnetin significantly inhibits malignant growth of metastatic esophageal squamous carcinoma cells and in-vivo ESCC metastatic tumors by inhibiting a fatty acid de novo synthesis pathway in tumor metabolism. Therefore, isorhamnetin can be used for developing an anti-ESCC metastatic cell growth medicine targeting an abnormally active fatty acid de novo anabolic enzyme.SELECTED DRAWING: Figure 1

The application relates to application of PFOI in preparation of a tumor cell ferroptosis-inducing drug and belongs to the technical field of medicines. The application provides application of PFOI in preparation of a tumor cell ferroptosis-inducing drug. The application verifies the correlation between PFOI and tumor cell ferroptosis through experiments, proves that PFOI can cause mitochondrial atrophy, membrane density increase and mitochondrial cristae reduction of cancer cells, cause ROS increase of the cancer cells, regulate GSH metabolism and fatty acid biosynthesis of the cancer cells, cause GSH exhaustion and lipid deposition, and promote the cancer cells to occur ferroptosis by inhibiting the expression of SLC7A11. Based on this, the application provides a new use of PFOI for inducing tumor cell ferroptosis, provides experimental basis and a new treatment strategy for clinical treatment of cancer, and provides new technical support for targeted treatment of cancer.

Method and compositions for treating glioblastoma (GBM) and other cancers is disclosed, involving the combination of radiation therapy (RT), fatty acid synthase (FASN) inhibitors, and programmed cell death protein 1 (PD-1) inhibitors or programmed death ligand 1 (PD-L1) inhibitors. The disclosed approach addresses the technical problem of RT-induced immunosuppression and resistance in cancers by targeting RT-induced lipid metabolism, which promotes immune escape. FASN inhibitors block fatty acid synthesis, enhancing immune cell infiltration and restoring anti-tumor immunity. PD-1 / PD-L1 inhibitors further counteract immunosuppressive pathways to improve therapeutic efficacy. This combination therapy prolongs survival, induces immune memory, and is applicable to other cancers, including those exhibiting increased lipid content post-RT or chemotherapy, including melanoma, breast cancer, and lung cancer.

Therapeutic combinations of fatty acid synthesis modulators and thyroid hormone receptor agonists are provided. The combinations may be used to treat disorders including metabolic disorders and liver disorders, such as nonalcoholic steatohepatitis / metabolic dysfunction-associated steatohepatitis (NASH / MASH).

Therapeutic combinations of a fatty acid synthesis modulator and a thyroid hormone receptor agonist are provided. The combinations are useful in the treatment of conditions, including metabolic conditions and liver conditions, such as non-alcoholic steatohepatitis / metabolic dysfunction associated steatohepatitis (NASH / MASH).

Methods of treating NASH / MASH comprising administering a fatty acid synthesis (FASN) inhibitor and compositions for treating the same are provided herein.

The application belongs to the technical field of fish lipid metabolism, and discloses application of 3-indolebutyric acid as a PPAR gamma agonist for regulating fish lipid metabolism. The application discloses that IBA can be used as a safe and effective peroxisome proliferator-activated receptor gamma (PPAR gamma) activator, and can be used for regulating fish peroxisome proliferator-activated receptor signal pathways, insulin signal pathways, glyceride metabolism signal pathways, fatty acid biosynthesis signal pathways, fatty acid elongation signal pathways and other metabolic pathways, promoting absorption and conversion of lipid substances such as triglycerides in fish, promoting production and accumulation of lipid substances such as free fatty acids and polyunsaturated fatty acids in fish, and having the effect of promoting fish growth, and has a wide application prospect.

The invention discloses application of an overexpressed BnaTOEs gene in increasing thousand seed weight and fatty acid content of cabbage type rape seeds. The BnaTOEs gene is a BnaTOE1 gene or a BnaTOE2 gene, the nucleotide sequences of DNA (deoxyribonucleic acid) of the BnaTOE1 gene and the BnaTOE2 gene are respectively shown as SEQ ID NO.1 and SEQ ID NO.2, the sequence lengths are respectively 1254bp and 1359bp, and the amino acid sequences of coded proteins are respectively shown as SEQ ID NO.3 and SEQ ID NO.4. The BnaTOEs gene and the BnaTOE2 gene have the advantages that the BnaTOE1 gene and the BnaTOE2 gene can be used for coding the BnaTOE1 gene and the BnaTOE2 gene; functional analysis of brassica napus genetic transformation shows that BnaTOE1 or BnaTOE2 participates in regulation and control of thousand seed weight and fatty acid synthesis and accumulation of brassica napus seeds, which is of great significance in promoting genetic improvement and breeding of brassica napus.

The application discloses modified potato resistant starch and application thereof in set yogurt, and comprises the following steps: adding chitosan oligosaccharide and zinc salt into potato PRS3 starch milk, mixing and treating, reacting with leucine-glycine dipeptide to obtain composite modified potato PRS3 starch; pre-gelatinizing the composite modified potato PRS3 starch, mixing with milk, mixing, homogenizing, sterilizing, inoculating and fermenting, and post-ripening to prepare set yogurt. 2+ The chitosan oligosaccharide-Zn 2+ and leucine-glycine dipeptide composite modified potato PRS3 starch forms a reversible three-dimensional coordination network and hydrophobic interaction, significantly improves transparency, freeze-thaw stability and resistance retention rate, and enhances the adsorption and combination capacity of milk protein and milk fat. The set yogurt has good gel strength, texture characteristics and sensory quality, effectively promotes the proliferation of probiotics, improves the coagulation efficiency, prevents whey separation and promotes the synthesis of intestinal short-chain fatty acids, and improves intestinal health.

This invention discloses the application of the transcription factor MaERF12 in regulating aroma release in banana fruits. This invention demonstrates that MaERF12 participates in the temperature-mediated transcriptional regulation of banana fruit aroma release by activating the transcription of MaHPL, MaADH, and MaAAT in the fatty acid synthesis pathway, affecting the amount and diversity of volatile substances released during banana fruit ripening. This invention provides a new perspective for understanding the transcriptional regulatory mechanisms related to aroma formation during banana ripening and provides a theoretical basis for precise regulation of banana fruit aroma metabolism.